Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175e10vq.htm |
| EX-2.1 - EX-2.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175exv2w1.htm |
| EX-10.1 - EX-10.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175exv10w1.htm |
| EX-10.2 - EX-10.2 - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175exv10w2.htm |
| EX-15.1 - EX-15.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175exv15w1.htm |
| EX-31.2 - EX-31.2 - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175exv31w2.htm |
| EX-31.1 - EX-31.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175exv31w1.htm |
| EX-32.1 - EX-32.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a54175exv32w1.htm |
Exhibit 15.2
November 2, 2009
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We are aware that our report dated November 2, 2009 on our review of interim financial
information of Valeant Pharmaceuticals International (the “Company”) for the three-month and
nine-month periods ended September 30, 2009 and 2008 and included in the Company’s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2009 is incorporated by reference in its
Registration Statements on Form S-3 (File No. 333-112904) and Form S-8 (File Nos. 33-56971,
333-81383, 333-73098, 333-85572, 333-109877, 333-109879, 333-142651, 333-156931 and 333-160393).
| Very truly yours, |
||||
| /s/ PricewaterhouseCoopers LLP | ||||